Guardant Health (GH) Expands Shield In India On Valuation Views Staying Closely Split
Guardant Health (GH) has come into focus after announcing an exclusive agreement with Zydus Lifesciences and a memorandum of understanding with Apollo Hospitals to introduce its Shield Multi Cancer Detection blood test in India.
See our latest analysis for Guardant Health.
Guardant Health's recent Shield partnerships land at a time when momentum in the stock has been strong, with a 30-day share price return of 21.60% and a 1-year total shareholder return of 218.51%, even after a recent one day pullback.
If this kind of healthcare and cancer screening story interests you, it may be worth widening your search to other companies using AI in medicine through the 41 healthcare AI stocks
Bulls point to Guardant Health's fast growing test portfolio and strong recent share price run, while bears focus on ongoing losses and execution risk around Shield. Which side does the current valuation appear to favor more?
Most Popular Narrative: 3.1% Overvalued
The most followed valuation narrative for Guardant Health places fair value at $155.25, slightly below the last close of $160.05. This frames a tight valuation gap that hinges on execution of its growth plans.
Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility.
Want to see what sits behind that confidence in Guardant Health's future cash flows? The narrative leans heavily on aggressive revenue expansion, margin uplift, and a very rich future earnings multiple that only makes sense once you see the full earnings and coverage path laid out.
Result: Fair Value of $155.25 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still meaningful risks to this Guardant Health story, particularly if Shield reimbursement or broader payer adoption falls short of current analyst expectations.
Find out about the key risks to this Guardant Health narrative.
Another View: SWS DCF Points To Undervaluation
The analyst narrative has Guardant Health looking slightly overvalued, but the SWS DCF model tells a different story. On this approach, Guardant Health's fair value is estimated at $186.19 per share versus a recent price of $160.05, suggesting the stock trades at a 14% discount. Which lens do you trust more for a long term decision?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Guardant Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Guardant Health inspires both optimism and concern, so if this story has your attention, move quickly to review the data and weigh the 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Guardant Health?
If Guardant Health has sharpened your interest in focused stock picking, do not stop here. Use the Simply Wall St Screener to uncover more targeted opportunities.
- Target potential mispriced opportunities by scanning for companies backed by strong fundamentals and attractive valuations using the 45 high quality undervalued stocks.
- Prioritize resilience and sleep better at night by searching for companies identified as 78 resilient stocks with low risk scores.
- Hunt for potential future standouts before the crowd by reviewing the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com